Cyclic AMP comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-22. Numbers and descriptions here follow the published literature rather than marketing material.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
According to CTV News Queen's Park Bureau Chief, Colin D'Mello, Premier Ford removed Fedeli as Finance Minister on June 20, 2019 in the "wake of a disastrous budget rollout that's left the Progressive Conservative government drowning in negative publicity." Minister Fedeli tabled the Ford government's first budget on April 11, 2019. According to the Sault Star, Fedeli was demoted from "highly-touted finance post" and "blamed" for the "failure to sell voters on the $163.4-billion budget and the cost of breaking a 10-year deal that ultimately expands beer and wine sales in grocery stores, costing taxpayers $1 billion." NDP Timiskaming-Cochrane MPP, John Vanthof, said that the 2019 budget failed northern Ontario by not providing funds for Highway 69, the Ring of Fire, expanded broadband access, and cuts to Indigenous Affairs, Ministry of Natural Resources, the Ministry of Agriculture, Food, and Rural Affairs, and more. Vanthof said that there "will be beer in corner stores, drinks at 9 in the morning, tailgate parties, and blue licence plates, but when the fog is cleared, there is also an over $500 million cut to the Ministry of Northern Development and Mines." In the fiscal year 2019, the publicly funded Legal Aid Ontario will receive $133 million less than previously, representing a funding cut of 30 per cent, as part of the Ford government's deficit-cutting plan, presented in the April 2019 budget.
== Hardware description == The 316 succeeded the earlier DDP-516 model and was promoted by Honeywell as suitable for industrial process control, data-acquisition systems, and as a communications concentrator and processor. The computer processor was made from small-scale integration DTL monolithic silicon integrated circuits. Most parts of the system operated at 2.5 MHz, and some elements were clocked at 5 MHz. The computer is a bitwise-parallel 2's complement system with 16-bit word length. The instruction set was a single-address type with an index register. Initially released with a capacity of 4096 through 16,384 words of memory, later expansion options allowed increasing memory space to 32,768 words. Memory cycle time is 1.6 microseconds; an integer register-to-register "add" instruction takes 3.2 microseconds. An optional hardware arithmetic option was available to implement integer multiply and divide, double-precision load and store, and double-precision (31-bit) integer addition and subtraction operations. It also provides a normalization operation, assisting implementation of software floating-point operations. The programmers' model of the H-316 consists of the following registers:
== Product development == The company's operations are divided into three segments: Custom Manufacturing Solutions, which develops APIs from pre-clinical to commercial stages; Generic Drug Substances, which manufactures non-exclusive APIs; and a Peptide API unit that specializes in peptide synthesis.
=== Anti-inflammation === Inhibiting inflammatory mediators could help prevent osteoarthritis progression. Cytokines and chemokines are both crucial in stimulating cartilage catabolism and blocking these inflammatory mediators. Studies have shown that treatment with NF-κB pathway inhibitor BAY11-7082 restores IL-1b-inhibited chondrogenesis of cartilage stem cells and in turn postpones progression of OA. Similarly, ample research shows that combined blockade of TNFa and IL-17 with bispecific antibodies reveals an inhibition of both cytokines for reduced cartilage degradation and proinflammatory responses.
Sources: en.wikipedia.org
=== Plants === Hydroxyproline rich glycoproteins (HRGPs) are also found in plant cell walls. These hydroxyprolines serve as the attachment points for glycan chains which are added as post-translational modifications.
==== Deposition ==== The extracellular matrix of bone is laid down by osteoblasts, which secrete both collagen and ground substance. These cells synthesise collagen alpha polypeptide chains and then secrete collagen molecules. The collagen molecules associate with their neighbors and crosslink via lysyl oxidase to form collagen fibrils. At this stage, they are not yet mineralized, and this zone of unmineralized collagen fibrils is called "osteoid". Around and inside collagen fibrils calcium and phosphate eventually precipitate within days to weeks becoming then fully mineralized bone with an overall carbonate substituted hydroxyapatite inorganic phase. In order to mineralise the bone, the osteoblasts secrete alkaline phosphatase, some of which is carried by vesicles. This cleaves the inhibitory pyrophosphate and simultaneously generates free phosphate ions for mineralization, acting as the foci for calcium and phosphate deposition. Vesicles may initiate some of the early mineralization events by rupturing and acting as a centre for crystals to grow on. Bone mineral may be formed from globular and plate structures, and via initially amorphous phases.
(Cm, Z=96): Curium-247, 1.64 × 107 years / 1.56 × 107 years (Am, Z=95): Americium-243; 7,370 years (Bk, Z=97): Berkelium-247; 1.4 × 103 years / 1380 years (Cf, Z=98): Californium-251; 898 years (Es, Z=99): Einsteinium-252; 471.7 days (Fm, Z=100): Fermium-257; 100.5 days (Md, Z=101): Mendelevium-258; 51.5 days (Lr, Z=103): Lawrencium-262; 3.6 hours = 216 minutes (No, Z=102): Nobelium-259; 58 minutes (Rf, Z=104): Rutherfordium-263; approximately 10 minutes (Sg, Z=106): Seaborgium-269; 5 ± 2 minutes (Bh, Z=107): Bohrium-270; approximately 61 seconds
== History == Insulin was discovered by Sir Frederick G Banting, Charles H Best, and JJR Macleod from the University of Toronto in 1921 as an injectable agent. German researchers first introduced the idea of inhalable insulin in 1924. Years of failure followed until scientists realized they might be able to use new technologies to turn insulin into a concentrated powder with particles sized for inhalation. In the 1980s Nektar Therapeutics, based on work by A. Carl Leopold on vitrifying proteins, developed technology to make insulin into small particles, technology then licensed to Pfizer. Alkermes developed a delivery device that they licensed to Eli Lilly and Company. Once concrete methods were developed, human tests began in the late 1990s. In January 2006, the U.S. Food and Drug Administration (FDA) approved the use of Exubera, a form of inhalable insulin developed by Pfizer. It was approved in the UK in August 2006 but reimbursed by the National Health Service only for people who had problems with needles. It was not reimbursed by any U.S. insurer. A 2007 systematic review concluded that the inhaled hexameric insulin (Exubera) "appears to be as effective, but no better than injected short-acting insulin. The additional cost is so much more that it is unlikely to be cost-effective." In 2007, Pfizer announced that it would no longer manufacture or market Exubera. According to Chairman and CEO Jeffrey Kindler this was because Exubera "failed to gain acceptance among patients and physicians".
According to a February 2015 Newsweek report, Houthis are fighting "for things that all Yemenis crave: government accountability, the end to corruption, regular utilities, fair fuel prices, job opportunities for ordinary Yemenis and the end of Western influence". In forming alliances, the Houthi movement has been at times opportunistic, partnering with countries it later declared as enemies, including the United States. The influx of various individual and tribal interests has somewhat diluted the movement's original vision over time. Around the time of the third Saada war (November 2005–February 2006), the conflict was increasingly waged "along the lines of prevalent tribal feuds", which distorted the initial socio-economic, religious and ideological aims of Hussein al-Houthi.
Sources: en.wikipedia.org
relaxation of muscle spasms prevention and retardation of disuse atrophy increase of local blood circulation muscle rehabilitation and re-education electrical muscle stimulation maintaining and increasing range of motion management of chronic and intractable pain including diabetic neuropathy acute post-traumatic and post-surgical pain post-surgical stimulation of muscles to prevent venous thrombosis wound healing drug delivery There is limited evidence supporting electrotherapy, specifically in treating musculoskeletal, osteoarthritis, fibromyalgia, neck pain, lumbopelvic pain, and ulcer conditions. Some of the treatment effectiveness mechanisms are little understood. The natural neurostimulation hypothesis explains the therapeutic effect by the fact that energy stimuli induce mitochondrial stress and microvascular vasodilation. Since healthy neurostimulation should emulate the physical characteristics of a mother's care for her fetus during pregnancy scaled to the treatment parameters of the specific patient, but many techniques of electrotherapy do not consider this, the hypothesis claims that their effectiveness and some practices associated with their use are still anecdotal.
== External links == Video of the Daisy ad, from the PBS website A Historical Look at Campaign Commercials The Emergence of the Maimed Hero Spy vs Spy Gallery Missile Command at the Killer List of Videogames
== History == The practice of salting fish dates back to ancient times. In classical antiquity, the town of Magdala on the Sea of Galilee, located in present-day Israel, was also known by its Greek name, Taricheae, meaning "place of fish salting." The Greek geographer Strabo even praised the quality of its fish (Geographica 16.2.45).
All sport in South Africa under apartheid was segregated by race, with separate clubs and governing bodies. Only white bodies were affiliated to the South African Olympic and Empire [later Commonwealth] Games Association (SAOEGA, later SAOCGA) so only white South Africans competed at the Olympic Games and the Empire (later Commonwealth) Games. The IOC under Avery Brundage regarded this as an internal matter for South Africa, and, committed to keeping politics and sports separate, took no action. From 1948, black athletes and their federations complained to the IOC about their exclusion, but were told to take the matter up with the SAOCGA. In the 1950s, NOCs from the Eastern Bloc led by the Soviet Union began to question this stance. With the decolonisation of Africa from the late 1950s, NOCs from newly independent states opposed to apartheid began affiliating to the IOC. However, the IOC itself was not representative of NOCs but rather a group of co-opted individuals, still mostly from First World countries. On the other hand, the international federations (IFs), the governing bodies of the Olympic sports, were quicker to give a voice to newer members.
A personal sense of responsibility is required for the pursuit of the values that give life meaning, but it is the realization that one holds sole responsibility for rendering life meaningful that allows the values to be actualized and life to be given true purpose. Determining what is meaningful for one's self provides a sense of autonomy and control which promotes self-esteem. Purpose in life is positively correlated with education level and volunteerism. However, it has also been found to decrease with age. Purpose in life is both highly individual, and what specifically provides purpose will change over the course of one's lifetime. All three of the above theories have self-esteem at their core. Self-esteem is often viewed as the most significant measure of psychological well-being, and highly correlated with many life-regulating skills. Purpose in life promotes and is a source of self-esteem; it is not a by-product of self-esteem.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.